Synairgen's (LSE:SNG) stock skyrocketed on Monday amid news that the largely unknown British respiratory therapeutics company had demonstrated in a phase 2 clinical trial that its inhalable drug SNG001 reduced the chances of coronavirus patients needing a ventilator by a stunning 79%.According to an interview conducted by the BBC, the company's head scientist operating the trial called the results "a game-changer," and went on to say that it could be "a major breakthrough" in the battle against COVID-19, a sentiment echoed nearly verbatim by an unaffiliated professor of metabolic medicine who was solicited for comments.